Case | HBS Case Collection | May 2000

To Trim or Not to Trim: That Is the Question

by Srikant M. Datar

Abstract

Should Novartis drop 20% of its global pharmaceutical product brands that account for only 3% of its pharmaceutical revenues?

Keywords: Business Earnings; Cost vs Benefits; Business Strategy; Investment Return; Problems and Challenges; Pharmaceutical Industry;

Citation:

Datar, Srikant M. "To Trim or Not to Trim: That Is the Question." Harvard Business School Case 100-105, May 2000.